SOURCE: Proteonomix

Proteonomix

December 02, 2010 12:41 ET

Proteonomix, Inc. (PROT) Announces Investor Update and New Company Website

MOUNTAINSIDE, NJ--(Marketwire - December 2, 2010) - Proteonomix, Inc. (OTCBB: PROT) ("Proteonomix" or the "Company") announced today that it has updated its corporate website (http://www.proteonomix.com/) to reflect the dynamic growth and investment opportunity that exists today.

Michael Cohen, CEO stated: "The mission of Proteonomix, Inc. is to achieve a leadership position in life enhancing regenerative stem cell therapies, services, and products through a combination of first to market technologies and innovative clinical trial strategies. Stem cell treatment provides much promise for the treatment of diseases previously regarded as incurable. Through years of research and development, Proteonomix has developed breakthroughs in stem cell therapies for disease and injury, identification biomarkers and reproductive cell/tissue laboratory services."

"Proteonomix is now actively negotiating strategic partnerships and opportunities for its breakthrough products and technology. We are currently in negotiations to joint venture our patents and intellectual properties with various entities and will be updating the investment community as these milestones are completed," concluded Mr. Cohen.

About Proteonomix, Inc.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.'s goal is the development of therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix's operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. ("PRTMI") intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies. Please also visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.otcqb.com/ and http://www.sec.gov/.

Forward-looking statements: Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. More specifically, the investment may never occur negating the agreement, product performance and/or side effects may necessitate termination of the joint venture, the implementation of the agreement may not succeed and inadequate or no business may develop causing the failure of the joint venture and there are inherent risks in foreign operations, particularly those in the Mideast. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

Contact Information

  • Contact:
    Public Relations:
    Constellation Asset Management, LLC
    415-524-8500